Advertisement

Topics

Zogenix’s Phase 3 Clinical Study Met all Endpoints

19:05 EDT 12 Jul 2018 | Investing News Network

Zogenix announced on Thursday (July 12) that its Phase 3 trial of ZX008 in Dravet syndrome met its primary and secondary endpoints, putting both regulatory submissions for the drug’s approval on pace for Q4 2018.

The post Zogenix’s Phase 3 Clinical Study Met all Endpoints appeared first on Investing News Network.

Original Article: Zogenix’s Phase 3 Clinical Study Met all Endpoints

NEXT ARTICLE

More From BioPortfolio on "Zogenix’s Phase 3 Clinical Study Met all Endpoints"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...